NVision Imaging

Otterspace raises $3.7m in pre-seed funding, launches private beta to coordinate internet-native organizations with non-transferable tokens

NVision Imaging

NVision has developed a quantum-based platform which polarizes natural metabolites, enabling these safe molecules to be used as an agent for imaging tumor metabolism via standard MRI. This safe imaging technology will provide clinicians worldwide unprecedented early insights into treatment efficacy, allowing non-responders to be moved onto another line of therapy more quickly. The company is based in Ulm, Germany, and active throughout the US and Europe.

DeepL to elevate AI research with new investment

Calvin Risk closes a $1.5M Pre-Seed round to help companies deploy and manage trustworthy AI

LatticeFlow Secures $12 Million to Accelerate Platform to Eliminate AI Data and Model Blind Spots in Computer Vision

Otterspace raises $3.7m in pre-seed funding, launches private beta to coordinate internet-native organizations with non-transferable tokens

Demoboost raises EUR 1.7 million pre-seed to transform how software is bought and sold

Ledgy raises $22 million Series B to fund European expansion

Part 1 | Mastering Product Management Basics: Vision & Roadmap

ottonova defies difficult market conditions, raising EUR 34 million

i2x receives €11 million in funding and appoints second managing director

SumUp raises €590 million and celebrates 10 years of supporting small merchants

NVision Imaging

Get to know NVision Imaging